Alpha Cognition Inc
Company Profile
Business description
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Contact
1200 - 750 West Pender Street
VancouverBCV6C 2T8
CANT: +1 604 564-9244
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.60 | 49.30 | -0.55% |
| CAC 40 | 8,099.46 | 25.42 | -0.31% |
| DAX 40 | 24,107.98 | 121.93 | -0.50% |
| Dow JONES (US) | 48,374.53 | 42.03 | -0.09% |
| FTSE 100 | 9,671.94 | 79.37 | -0.81% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 23,113.47 | 56.06 | 0.24% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,424.95 | 16.81 | 0.13% |
| S&P 500 | 6,816.12 | 0.39 | -0.01% |
| S&P/ASX 200 | 8,598.90 | 48.40 | -0.56% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |